Tuesday, 08 September 2026 12:32 PM
Class Action
NEW YORK CITY, NY / ACCESS Newswire / September 8, 2026 / Levi & Korsinsky, LLP announces that a securities class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Beta Bionics, Inc. (NASDAQ:BBNX) securities.
If you suffered a loss on your Beta Bionics, Inc. investment and would like to explore a potential recovery under the federal securities laws, Learn about Beta Bionics, Inc. Class Action or contact Joseph E. Levi, Esq. via email at [email protected] or call (212)363-7500 to speak to our team of experienced shareholder advocates.
THE LAWSUIT: A class action securities lawsuit was filed against Beta Bionics, Inc. that seeks to recover losses of shareholders who were adversely affected by alleged securities fraud between July 30, 2025 and February 24, 2026.
CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: According to the filed complaint, defendants made false and/or misleading statements and/or failed to disclose that: when they portrayed the Form 483 as relating only to a difference of interpretation of reportable events and downplayed the seriousness of those events. Saint's and Feider's statements in were misleading because they touted iLet's performance but omitted the thousands of safety complaints the Company had received. It was misleading for Saint to tell investors, that the Form 483 concerned only a minor difference in interpretation of reporting rules, and that the complaints to be back-filed were only benign reports requiring no hospitalization, when, in fact, the Form 483 identified over 18,000 complaints out of less than 30,000 total iLet users, including numerous life-threatening hypoglycemic events that the Company had "failed to investigate," or even report to the FDA, with no justification. Saint and Feider further misled investors by assuring them that the Company's remediation efforts were advanced and the FDA's issues were very benign," when they failed to accurately describe the scope and severity of the FDA's observations which made remediation much more complex and extensive than defendants indicated to investors. Lastly, it was misleading for Saint to stress that complaint could be extremely benign, and that there was no "underlying problem in our data here," while omitting that the Company had in fact received hundreds of complaints of life-threatening events requiring hospitalization, and that the FDA had raised this issue in its Form 483.
WHAT'S NEXT? If you purchased Beta Bionics, Inc. stock during the relevant time frame - even if you still hold your shares, learn about your rights to seek a recovery. There is no cost or obligation to participate.
WHY LEVI & KORSINSKY: Over the past 20 years, Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States. Attorney Advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
[email protected]
Tel: (212)363-7500
Fax: (212) 363-7171
SOURCE: Levi & Korsinsky, LLP